Bullish indicating open at $55-$60, IPO prices at $37
Investing.com -- Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) stock jumped 7.4% after announcing a clinical study agreement with AGEPHA Pharma to examine treatment for inflammation-driven coronary heart disease.
The collaboration will utilize AGEPHA’s FDA-approved low-dose colchicine medication, LODOCO, in a Cardio Diagnostics-sponsored study. The research will employ Cardio’s PrecisionCHD blood test to identify suitable patients with inflammation-driven coronary heart disease, who will then be prescribed LODOCO when clinically appropriate.
Patients will undergo retesting to examine changes in inflammation markers through DNA methylation signatures. The PrecisionCHD test uses artificial intelligence to analyze six DNA methylation markers corresponding to modifiable drivers of coronary heart disease, including inflammation.
"This study reflects a precision medicine model where diagnosis and treatment are both guided by the patient’s unique molecular insights," said Robert Philibert, chief medical officer at Cardio Diagnostics.
Cardio Diagnostics is currently evaluating potential clinical sites for the study. The final study design will be developed with the principal investigator at selected clinical sites and registered as a clinical trial.
The initiative aligns with the American Heart Association’s recent $15 million commitment to studying inflammation’s impact on cardiovascular and brain health. The collaboration aims to validate what the company describes as a precision-guided approach to treating inflammation-driven coronary heart disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.